# South America Anti VEGF Market > South America Anti-VEGF Market Research Report: Size, Share, Trend Analysis By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration) and By Region (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 1.31% - **2024:** $ 1,818.88 Million - **2025:** $ 1,842.71 Million - **2035:** $ 2,100 Million - **Key Players:** Regeneron Pharmaceuticals (US), Roche Holding (CH), Novartis (CH), Bayer AG (DE), Pfizer Inc. (US), Amgen Inc. (US), Santen Pharmaceutical (JP), Eli Lilly and Company (US), Hikma Pharmaceuticals (GB) **Report ID:** MRFR/HC/50413-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-anti-vegf-market-52171 --- ## Market Summary ## **South America Anti-VEGF Market Overview** ### As per MRFR analysis, the South America Anti-VEGF Market Size was estimated at 1.25 (USD Billion) in 2023. The South America Anti-VEGF Market Industry is expected to grow from 1.3(USD Billion) in 2024 to 2.07 (USD Billion) by 2035. The South America Anti-VEGF Market CAGR (growth rate) is expected to be around 4.313% during the forecast period (2025 - 2035). ### **Key South America Anti-VEGF Market Trends Highlighted** The South America Anti-VEGF market is undergoing substantial growth, which is primarily due to the rising prevalence of retinal disorders, including diabetic retinopathy and age-related macular degeneration (AMD). The prevalence of these conditions is increasing as a result of the ageing population and the increasing prevalence of diabetes in countries such as Argentina and Brazil.  Furthermore, the healthcare infrastructure in South America is enhancing, with a rise in investments in ophthalmic care, which is resulting in higher rates of diagnosis and treatment. The availability of sophisticated therapies and medications is also a significant market driver, as a variety of anti-VEGF agents are now available, which has improved the treatment options available to patients. There are significant opportunities to be investigated as the market evolves, particularly in the expansion of treatment accessibility in rural and underserved regions.  A more proactive approach to seeking medical assistance may result from the increasing awareness of the significance of eye health among citizens. The market can be further expanded by increasing the number of patients pursuing Anti-VEGF treatments through public health initiatives that are designed to educate the population about retinal diseases. Pharmaceutical companies and healthcare providers have been collaborating more frequently in recent years to enhance patient outcomes and treatment protocols. In the field of ophthalmology, there is a growing trend towards personalized medicine, as tailored therapies are gaining traction. Additionally, the landscape of anti-VEGF therapy in South America may be altered by the development of innovative drug delivery systems, including sustained release implants and nanotechnology-based treatments. In general, the region's market is dynamic and evolving, as evidenced by the convergence of these drivers and emergent trends. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **South America Anti-VEGF Market Drivers** ### **Rising Incidence of Eye Diseases** The South America Anti-Vascular Endothelial Growth Factor (VEGF) Market Industry is primarily driven by the increasing prevalence of eye diseases such as diabetic retinopathy and age-related macular degeneration. According to the Pan American Health Organization, the rate of diabetes in South America has been steadily rising, with an estimated 16 million individuals affected in the region, leading to increased incidence of related complications such as diabetic retinopathy.This surge in eye diseases necessitates effective treatment options, including anti-VEGF therapies, thus fueling demand in the South America Anti-VEGF Market. Established pharmaceutical companies like Novartis and Roche, which focus extensively on R&D for innovative anti-VEGF treatments, play a significant role in addressing this growing need. Their involvement not only boosts treatment availability but also raises awareness about the importance of early diagnosis and intervention, further enhancing market growth potential. ### **Advancements in Treatment Modalities** Technological advancements in treatment modalities for eye diseases are another strong driver of the South America Anti-VEGF Market Industry. The integration of innovative drug delivery systems, such as sustained release formulations and ocular implants, has improved patient compliance and outcomes significantly. For instance, recent developments by companies like Alimera Sciences in sustained-release delivery systems provide a competitive edge in the market.Additionally, the Brazilian Health Regulatory Agency (ANVISA) has streamlined the approval process for new anti-VEGF therapies, encouraging more investments in Research and Development. The introduction of advanced treatment options not only expands the accessibility for patients across South America but also enhances the growth trajectory of the market. ### **Growing Geriatric Population** The increasing proportion of the aging population in South America is a notable driver for the Anti-Vascular Endothelial Growth Factor (VEGF) Market Industry. With the World Health Organization projecting that the number of older adults (aged 60 years and above) in South America will surpass 85 million by 2050, the demand for effective treatments for age-related eye conditions is set to rise dramatically. This demographic transformation indicates a higher likelihood of chronic eye diseases, consequently escalating the need for anti-VEGF therapies.Organizations like the International Federation on Aging emphasize the importance of accessible healthcare solutions for this demographic, leading to partnerships with pharmaceutical firms to develop targeted therapies for age-related macular degeneration, thereby propelling market growth for anti-VEGF solutions in the region. ## **South America Anti-VEGF Market Segment Insights** ### **Anti-VEGF Market Product Insights** The South America Anti-VEGF Market segment, particularly focused on Product, is experiencing notable growth, driven by an increasing prevalence of retinal disorders and the growing aging population in the region. Anti-VEGF therapies play a crucial role in treating conditions such as age-related macular degeneration and diabetic retinopathy, highlighting their importance in ophthalmic care. Within this segment, Eylea has emerged as a leading treatment due to its effective long-term results and favorable dosing schedule, which has helped it capture a significant market share. Lucentis remains a vital player as well, widely recognized for its efficacy in managing certain eye diseases, and is frequently used in clinical settings across various South American countries. Beovu, while newer in the market, is gaining traction due to its innovative formulation that promises improved outcomes for patients with serious retinal diseases. The overall dynamics in the South America Anti-VEGF Market are compelling, as factors like ongoing Research and Development efforts, advancements in drug formulations, and increased awareness about ocular health are shaping the landscape.Additionally, collaborations between pharmaceutical companies and healthcare providers are enhancing access to these therapies, ultimately supporting the market's expansion. Overall, the Product segment within the South America Anti-VEGF Market presents significant opportunities for stakeholders due to its essential role in addressing pressing healthcare needs in the region's population. ### **Anti-VEGF Market Disease Insights** The South America Anti-VEGF Market within the Disease segment encompasses several critical conditions that necessitate targeted treatment, notably including Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, and Age-Related Macular Degeneration. Focused on addressing vision impairments caused by these diseases, the market experiences significant demand due to the rising prevalence of diabetes and the aging population in South America. Macular Edema often results from diabetes, highlighting the intersection of these health challenges and underscoring the need for effective anti-VEGF therapies. Diabetic Retinopathy is a leading cause of blindness in working-age adults, making it a priority within healthcare systems in the region. Retinal Vein Occlusion also contributes significantly to vision loss, creating urgency for effective treatment solutions. Meanwhile, Age-Related Macular Degeneration continues to be a pressing concern as the population ages, creating a growing market for anti-VEGF drugs. Overall, the Disease segment within the South America Anti-VEGF Market reflects a landscape shaped by the increasing incidence of these conditions, driving innovation and therapeutic development aimed at improving patient outcomes and addressing significant public health challenges. ### **Anti-VEGF Market Regional Insights** The South America Anti-VEGF Market exhibits a dynamic landscape, particularly driven by key countries like Brazil, Mexico, and Argentina. Brazil leads the market due to its substantial healthcare spending and a growing patient population suffering from retinal diseases, making it a focal point for anti-VEGF treatments. Mexico also presents significant opportunities, bolstered by increasing awareness and acceptance of advanced therapies among healthcare professionals and patients.  Argentina, while smaller in comparison, is experiencing a rise in government initiatives aimed at improving eye care services, which fuels the demand for anti-VEGF treatments.A diverse range of healthcare systems and varying levels of access to anti-VEGF therapies characterize the Rest of South America. Overall, the South America Anti-VEGF Market reflects a promising trajectory with increasing focus on improving healthcare infrastructure, expanding patient access, and addressing unmet medical needs across the region. Factors such as a rising geriatric population, increased prevalence of degenerative eye disorders, and advancements in pharmaceutical research play pivotal roles in shaping the market dynamics. With ongoing developments in healthcare policies and an emphasis on telemedicine, the region presents numerous growth opportunities for industry players. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ## **South America Anti-VEGF Market Key Players and Competitive Insights** The South America Anti-VEGF market has witnessed substantial growth due to the increasing prevalence of ocular diseases, particularly age-related macular degeneration and diabetic retinopathy. The competitive landscape is characterized by a mix of established companies and emerging players, all striving to capture market share through innovative product formulations, strategic partnerships, and extensive distribution networks. Key factors influencing competition include the introduction of biosimilars, advancements in research and development, and the growing emphasis on patient-centric solutions. Companies are also focusing on strengthening their presence in the market by expanding their product portfolios and enhancing accessibility to anti-VEGF therapies across diverse regions in South America. Hikma Pharmaceuticals has established itself as a significant player in the South America Anti-VEGF market. With a robust portfolio that includes both generic and branded medications, the company is well-positioned to leverage its strengths in manufacturing and distribution within the region. Hikma's commitment to high-quality standards, combined with its diverse range of formulations, has allowed it to meet varying market demands effectively. The company's strategies to collaborate with healthcare professionals and engage in educational campaigns further enhance its visibility and acceptance in the region. By optimizing its supply chain and focusing on operational efficiencies, Hikma has managed to create a competitive edge that secures its position in the South American market. Eisai has also made notable strides in the South America anti-VEGF market, particularly with its innovative product offerings that address significant unmet medical needs. The company's focus on research and development enables it to provide cutting-edge therapies that cater to the diverse patient demographics in the region. Eisai's strategic partnerships with local distributors have facilitated greater market penetration and accessibility for its key services and products. Through targeted marketing initiatives and educational programs, Eisai is able to build strong relationships with healthcare providers, enhancing its brand recognition. Recent mergers and acquisitions have further strengthened Eisai’s market presence, allowing it to expand its portfolio and usher in new technologies focused on improving patient outcomes in the South American anti-VEGF landscape. ### **Key Companies in the South America Anti-VEGF Market Include** ### **South America Anti-VEGF Market Industry Developments** The South America Anti-VEGF Market has recently seen significant developments, with companies like Novartis and Regeneron Pharmaceuticals actively expanding their market presence. In March 2023, Novartis unveiled robust results from clinical trials supporting the efficacy of their anti-VEGF treatments, which are expected to bolster their share in the region. On the competitive front, Alliances between Hikma Pharmaceuticals and local biotech firms have fostered advancements in product distribution, with multiple launches projected for the coming year.In terms of market dynamics, the growing prevalence of retinal diseases in South America is driving a surge in demand for anti-VEGF therapies. As of October 2023, Amgen and Pfizer reported significant growth in their market valuation as a result of increased investments in Research and Development and expanded access programs, positively impacting overall market health. The health authorities are also ramping up efforts to ensure better accessibility to anti-VEGF treatments, acknowledging the rising disease burden.No recent mergers or acquisitions involving the specified companies have been publicly disclosed in this sector. However, Santen Pharmaceutical's strategic partnerships with regional players hint at potential future consolidations. ## **South America Anti-VEGF Market Segmentation Insights** ### **Anti-VEGF Market Product Outlook** ### **Anti-VEGF Market Disease Outlook** ### **Anti-VEGF Market Regional Outlook** ## Market Drivers ### Rising Geriatric Population The increasing geriatric population in South America is a notable driver for the anti vegf market. As individuals age, the risk of developing age-related macular degeneration and other retinal diseases escalates. Current estimates suggest that by 2030, the population aged 65 and older in South America will exceed 100 million. This demographic shift is likely to result in a higher incidence of retinal diseases, thereby increasing the demand for anti-VEGF therapies. The anti vegf market must adapt to this growing need by ensuring the availability of effective treatment options tailored to the elderly, thus fostering market expansion. ### Government Initiatives for Eye Health Government initiatives aimed at improving eye health in South America are expected to bolster the anti vegf market. Various health ministries are implementing programs to raise awareness about retinal diseases and promote early diagnosis and treatment. These initiatives often include funding for public health campaigns and subsidized access to medications, including anti-VEGF therapies. For instance, some countries have allocated budgets exceeding $10 million annually to combat vision impairment caused by retinal diseases. Such efforts not only enhance patient access to necessary treatments but also encourage healthcare providers to adopt anti-VEGF therapies as standard care, thus driving market growth. ### Technological Advancements in Drug Delivery Technological advancements in drug delivery systems are poised to transform the anti vegf market in South America. Innovations such as sustained-release formulations and targeted delivery mechanisms are enhancing the efficacy of anti-VEGF therapies. These advancements may lead to improved patient compliance and reduced treatment frequency, which is particularly beneficial in regions with limited healthcare access. The market for anti-VEGF treatments is projected to grow by approximately 15% annually, driven by these technological improvements. As healthcare providers increasingly adopt these advanced delivery systems, the anti vegf market is likely to experience significant growth, catering to the evolving needs of patients. ### Increasing Prevalence of Diabetic Retinopathy The rising prevalence of diabetic retinopathy in South America is a critical driver for the anti vegf market. As diabetes rates continue to escalate, the number of individuals affected by this sight-threatening condition is projected to increase significantly. Reports indicate that approximately 30% of diabetic patients may develop diabetic retinopathy, leading to a growing demand for effective treatment options. The anti vegf market is likely to benefit from this trend, as anti-VEGF therapies have shown efficacy in managing the progression of the disease. Furthermore, the increasing awareness of diabetic complications among healthcare providers and patients may further stimulate the demand for anti-VEGF treatments, thereby enhancing market growth in the region. ### Rising Investment in Healthcare Infrastructure Rising investment in healthcare infrastructure across South America is expected to positively impact the anti vegf market. Governments and private entities are increasingly allocating funds to enhance healthcare facilities, improve diagnostic capabilities, and expand access to advanced treatments. For instance, several countries have reported investments exceeding $5 billion in healthcare infrastructure over the past few years. This influx of capital is likely to facilitate the adoption of anti-VEGF therapies, as healthcare providers gain access to better resources and training. Consequently, the anti vegf market is anticipated to grow as healthcare systems become more equipped to manage retinal diseases effectively. ## Future Outlook The [Anti VEGF Market](https://www.marketresearchfuture.com/reports/anti-vegf-market-21963) is projected to grow at 1.31% CAGR from 2025 to 2035, driven by increasing prevalence of retinal diseases and advancements in treatment options. **New opportunities:** - Development of biosimilars to enhance market access and affordability. - Expansion of telemedicine platforms for remote patient monitoring and consultations. - Strategic partnerships with local healthcare providers to improve distribution channels. By 2035, the anti-VEGF market is expected to solidify its position, driven by innovation and strategic collaborations. ## Segment Insights ### By Product: Eylea (Largest) vs. Beovu (Fastest-Growing) The anti VEGF market is characterized by a competitive landscape with leading products like Eylea, Lucentis, and Beovu. Eylea holds a substantial share, reflecting its established presence and physician preference. Lucentis, while still significant, has faced challenges as newer therapies emerge. Beovu, although currently smaller in terms of market share, is rapidly gaining traction due to its innovative formulation and favorable dosing schedule. Growth in this segment is driven by increasing prevalence of age-related macular degeneration and diabetic retinopathy, leading to higher demand for anti VEGF therapies. The rise in diabetes rates and an aging population contribute to this trend. Furthermore, advancements in product formulations, including improved administration methods, are expected to enhance patient adherence and encourage the uptake of newer therapies like Beovu, positioning it as a key player in the future. Eylea (Dominant) vs. Beovu (Emerging) Eylea has established itself as the dominant player in the market due to its comprehensive efficacy and safety profile, leading to widespread acceptance by healthcare professionals. Its extended dosing interval has garnered loyalty among patients, contributing to its sustained popularity. In contrast, Beovu is emerging as a significant contender, appealing to both patients and physicians with its novel formulation that allows for less frequent dosing. This characteristic addresses a crucial need for improved convenience, making Beovu attractive in the treatment landscape. As awareness of Beovu's benefits grows and clinical experience increases, its market share is expected to expand rapidly, positioning it as a key product in future treatment regimens. ### By Disease: Macular Edema (Largest) vs. Diabetic Retinopathy (Fastest-Growing) In the South America anti vegf market, Macular Edema holds the largest share, significantly dominating the landscape due to its high prevalence among patients suffering from diabetes and other ocular conditions. Diabetic Retinopathy, while not the largest, is gaining traction rapidly as awareness and screening initiatives expand, thus contributing to its share in the market. The competition among various anti-VEGF therapies further enhances the market dynamics within these segments. Growth in the South America anti vegf market is driven by a rise in ocular diseases as the population ages and diabetes cases increase. Innovations in treatment protocols and a shift towards early interventions are propelling the market forward. Additionally, the accessibility of advanced therapies is expected to bolster the growth of Diabetic Retinopathy, making it an area to watch closely as healthcare systems evolve in the region. Macular Edema: Dominant vs. Diabetic Retinopathy: Emerging Macular Edema represents the dominant segment in the South America anti vegf market due to its critical implications in vision loss, attracting substantial investment from pharmaceutical companies. This segment benefits from a well-established treatment framework and extensive clinical data supporting its therapies. On the other hand, Diabetic Retinopathy is emerging as a key segment, fueled by increasing incidences among diabetic populations and ongoing research into novel treatment options. This segment is characterized by a growing number of healthcare initiatives aimed at improving awareness and access to treatments, ultimately positioning it for significant growth in the coming years. ## Regional Market Share Analysis ### Brazil : Leading Market with Robust Growth Brazil holds a commanding market share of 50.5% in the South American anti-VEGF market, valued at $850.0 million. Key growth drivers include increasing prevalence of retinal diseases and government initiatives promoting healthcare access. The demand for innovative therapies is rising, supported by favorable regulatory policies that streamline drug approvals. Infrastructure improvements in healthcare facilities further bolster market growth, enhancing patient access to treatments. ### Mexico : Growth Driven by Healthcare Reforms Mexico accounts for 18.5% of the South American anti-VEGF market, valued at $300.0 million. The market is driven by healthcare reforms aimed at improving access to treatments and increasing awareness of retinal diseases. Demand is growing in urban areas, particularly in Mexico City and Guadalajara, where healthcare infrastructure is being enhanced. Regulatory support for innovative therapies is also a key factor, fostering a competitive environment for major players. ### Argentina : Strong Demand Amid Economic Challenges Argentina represents 25.5% of the South American anti-VEGF market, valued at $400.0 million. The market is driven by rising incidences of age-related macular degeneration and diabetic retinopathy. Government initiatives to improve healthcare access and affordability are crucial, despite economic challenges. The competitive landscape includes significant players like Novartis and Roche, with Buenos Aires being a key market due to its advanced healthcare facilities and patient population. ### Rest of South America : Diverse Opportunities Across Regions The Rest of South America holds a market share of 16.0%, valued at $268.88 million. This sub-region includes countries like Chile, Colombia, and Peru, where demand for anti-VEGF therapies is growing due to increasing awareness and healthcare improvements. Local regulations are evolving to support innovative treatments, creating a favorable business environment. Key players like Bayer and Amgen are expanding their presence, focusing on regional healthcare needs and partnerships. ## Competitive Benchmarking The anti-VEGF market in South America is characterized by a dynamic competitive landscape, driven by increasing prevalence of retinal diseases and a growing aging population. Key players such as Regeneron Pharmaceuticals (US), Roche Holding (CH), and Novartis (CH) are strategically positioned to leverage innovation and regional expansion. Regeneron Pharmaceuticals (US) focuses on enhancing its product portfolio through continuous research and development, while Roche Holding (CH) emphasizes partnerships to bolster its market presence. Novartis (CH) is actively pursuing mergers and acquisitions to consolidate its position, indicating a trend towards a more concentrated market structure.The market appears moderately fragmented, with several players vying for dominance. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This strategic focus on operational excellence is likely to influence competitive dynamics, as firms seek to differentiate themselves through superior service delivery and product availability. In October Regeneron Pharmaceuticals (US) announced a collaboration with a local biotech firm to develop a novel delivery system for its anti-VEGF therapies. This strategic move is expected to enhance patient access and streamline distribution channels, thereby reinforcing Regeneron’s competitive edge in the region. Such partnerships may also facilitate quicker adaptation to local market needs, which is crucial in a diverse landscape like South America. In September Roche Holding (CH) launched a new digital platform aimed at improving patient engagement and adherence to anti-VEGF treatments. This initiative reflects a growing trend towards digitalization in healthcare, suggesting that Roche is keen on integrating technology to enhance patient outcomes. By leveraging data analytics, the company may gain insights into treatment efficacy and patient behavior, potentially leading to improved product offerings. In August Novartis (CH) completed the acquisition of a smaller firm specializing in innovative drug delivery systems. This acquisition is likely to bolster Novartis’s capabilities in the anti-VEGF segment, allowing for the development of more effective therapies. The strategic importance of this move lies in its potential to enhance Novartis’s competitive positioning by expanding its product pipeline and addressing unmet medical needs in the region. As of November the competitive trends in the anti-VEGF market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards innovation, technology, and supply chain reliability. This transition may ultimately reshape the landscape, fostering a more sustainable and patient-centric approach in the anti-VEGF market. ## Recent News & Developments The South America Anti-VEGF Market has recently seen significant developments, with companies like Novartis and Regeneron Pharmaceuticals actively expanding their market presence. In March 2023, Novartis unveiled robust results from clinical trials supporting the efficacy of their anti-VEGF treatments, which are expected to bolster their share in the region. On the competitive front, Alliances between Hikma Pharmaceuticals and local biotech firms have fostered advancements in product distribution, with multiple launches projected for the coming year.In terms of market dynamics, the growing prevalence of retinal diseases in South America is driving a surge in demand for anti-VEGF therapies. As of October 2023, Amgen and Pfizer reported significant growth in their market valuation as a result of increased investments in Research and Development and expanded access programs, positively impacting overall market health. The health authorities are also ramping up efforts to ensure better accessibility to anti-VEGF treatments, acknowledging the rising disease burden.No recent mergers or acquisitions involving the specified companies have been publicly disclosed in this sector. However, Santen Pharmaceutical's strategic partnerships with regional players hint at potential future consolidations. ## Report Scope | MARKET SIZE 2024 | 1818.88(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1842.71(USD Million) | | MARKET SIZE 2035 | 2100.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 1.31% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Regeneron Pharmaceuticals (US), Roche Holding (CH), Novartis (CH), Bayer AG (DE), Pfizer Inc. (US), Amgen Inc. (US), Santen Pharmaceutical (JP), Eli Lilly and Company (US), Hikma Pharmaceuticals (GB) | | Segments Covered | Product, Disease | | Key Market Opportunities | Emerging biologics and personalized therapies drive growth in the anti vegf market. | | Key Market Dynamics | Rising demand for innovative anti-VEGF therapies driven by increasing prevalence of retinal diseases in South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What was the overall market valuation of the anti-VEGF market in 2024?** A: The overall market valuation was $1818.88 Million in 2024. **Q: What is the projected market valuation for the anti-VEGF market in 2035?** A: The projected market valuation for 2035 is $2100.0 Million. **Q: What is the expected CAGR for the anti-VEGF market during the forecast period 2025 - 2035?** A: The expected CAGR for the anti-VEGF market during the forecast period 2025 - 2035 is 1.31%. **Q: Which product segment had the highest valuation in 2024?** A: In 2024, the product segment Eylea had the highest valuation at $1200.0 Million. **Q: How did the valuation of Lucentis compare to Beovu in 2024?** A: In 2024, Lucentis was valued at $700.0 Million, whereas Beovu was valued at $218.88 Million. **Q: What was the valuation of the Macular Edema segment in 2024?** A: The Macular Edema segment was valued at $600.0 Million in 2024. **Q: Which disease segment is projected to have the highest valuation in 2035?** A: The Diabetic Retinopathy segment is projected to have the highest valuation in 2035, likely reaching $700.0 Million. **Q: What are the key players in the anti-VEGF market?** A: Key players in the anti-VEGF market include Regeneron Pharmaceuticals, Roche Holding, Novartis, Bayer AG, Pfizer Inc., Amgen Inc., Santen Pharmaceutical, Eli Lilly and Company, and Hikma Pharmaceuticals. **Q: What was the valuation of the Age-Related Macular Degeneration segment in 2024?** A: The Age-Related Macular Degeneration segment was valued at $318.88 Million in 2024. **Q: How does the projected growth of the anti-VEGF market reflect on the competitive landscape?** A: The projected growth of the anti-VEGF market suggests that key players may intensify their competitive strategies to capture market share as the valuation increases. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-anti-vegf-market-52171*